DE69613984D1 - Für die protein-kinase a-spezifische modifizierte oligonukleotide und verfahren zur deren verwendung - Google Patents
Für die protein-kinase a-spezifische modifizierte oligonukleotide und verfahren zur deren verwendungInfo
- Publication number
- DE69613984D1 DE69613984D1 DE69613984T DE69613984T DE69613984D1 DE 69613984 D1 DE69613984 D1 DE 69613984D1 DE 69613984 T DE69613984 T DE 69613984T DE 69613984 T DE69613984 T DE 69613984T DE 69613984 D1 DE69613984 D1 DE 69613984D1
- Authority
- DE
- Germany
- Prior art keywords
- protein kinase
- oligonucleotids
- specific modified
- oligonucleotides
- disclosed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 102000001253 Protein Kinase Human genes 0.000 title 1
- 108060006633 protein kinase Proteins 0.000 title 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical class Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 4
- 108091034117 Oligonucleotide Proteins 0.000 abstract 2
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 abstract 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 230000002222 downregulating effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/532,979 US5969117A (en) | 1995-08-17 | 1995-09-22 | Modified protein kinase a-specific oligonucleotide |
PCT/US1996/015084 WO1997011171A1 (en) | 1995-09-22 | 1996-09-19 | Modified protein kinase a-specific oligonucleotides and methods of their use |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69613984D1 true DE69613984D1 (de) | 2001-08-23 |
DE69613984T2 DE69613984T2 (de) | 2001-11-29 |
Family
ID=24123968
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69613984T Expired - Fee Related DE69613984T2 (de) | 1995-09-22 | 1996-09-19 | Für die protein-kinase a-spezifische modifizierte oligonukleotide und verfahren zur deren verwendung |
Country Status (8)
Country | Link |
---|---|
US (1) | US5969117A (de) |
EP (1) | EP0846170B1 (de) |
JP (1) | JPH11512601A (de) |
AT (1) | ATE203271T1 (de) |
AU (1) | AU7241296A (de) |
CA (1) | CA2232724A1 (de) |
DE (1) | DE69613984T2 (de) |
WO (1) | WO1997011171A1 (de) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6608035B1 (en) * | 1994-10-25 | 2003-08-19 | Hybridon, Inc. | Method of down-regulating gene expression |
US6645943B1 (en) | 1994-10-25 | 2003-11-11 | Hybridon, Inc. | Method of down-regulating gene expression |
US6624293B1 (en) * | 1995-08-17 | 2003-09-23 | Hybridon, Inc. | Modified protein kinase A-specific oligonucleotides and methods of their use |
US7074768B2 (en) * | 1995-08-17 | 2006-07-11 | Idera Pharmaceuticals, Inc. | Modified protein kinase A-specific oligonucleotides and methods of their use |
US5886165A (en) * | 1996-09-24 | 1999-03-23 | Hybridon, Inc. | Mixed backbone antisense oligonucleotides containing 2'-5'-ribonucleotide- and 3'-5'-deoxyribonucleotides segments |
JP2002501370A (ja) * | 1997-03-12 | 2002-01-15 | ハイブライドン,インク. | 改良蛋白質キナーゼa特性オリゴヌクレオチドおよびその利用方法 |
US7192932B1 (en) | 1997-04-29 | 2007-03-20 | Lauras As | Use of immunomodulating agents |
NO971997D0 (no) * | 1997-04-29 | 1997-04-29 | Kjetil Tasken | Bruk av immunmodulerende midler |
AU766674B2 (en) * | 1998-05-27 | 2003-10-23 | Lauras As | Method |
US20030105037A1 (en) * | 2001-10-06 | 2003-06-05 | Isis Pharmaceuticals Inc. | Antisense modulation of inhibitor-kappa B kinase-gamma expression |
US7528117B2 (en) * | 2002-12-05 | 2009-05-05 | The Research Foundation Of State University Of New York | High efficacy antisense RIαPKA poly-DNP oligoribonucleotides |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5220007A (en) * | 1990-02-15 | 1993-06-15 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of RNA and production of encoded polypeptides |
US5470967A (en) * | 1990-04-10 | 1995-11-28 | The Dupont Merck Pharmaceutical Company | Oligonucleotide analogs with sulfamate linkages |
US5271941A (en) * | 1990-11-02 | 1993-12-21 | Cho Chung Yoon S | Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases |
US5652355A (en) * | 1992-07-23 | 1997-07-29 | Worcester Foundation For Experimental Biology | Hybrid oligonucleotide phosphorothioates |
JPH07505057A (ja) * | 1993-01-21 | 1995-06-08 | ザ サルク インスティテュート フォー バイオロジカル スタディーズ | プロテインキナーゼ |
EP0693123A1 (de) * | 1993-03-31 | 1996-01-24 | HYBRIDON, Inc. | Veränderte Oligonukleotide mit verbesserter anti-grippe Aktivität |
JPH1135595A (ja) * | 1994-12-02 | 1999-02-09 | Pola Chem Ind Inc | アンチセンスオリゴヌクレオチド及びそれを用いた制癌剤 |
WO1996031600A1 (en) * | 1995-04-03 | 1996-10-10 | Hybridon, Inc. | Method of modulating gene expression without depleting complement |
-
1995
- 1995-09-22 US US08/532,979 patent/US5969117A/en not_active Expired - Lifetime
-
1996
- 1996-09-19 WO PCT/US1996/015084 patent/WO1997011171A1/en active IP Right Grant
- 1996-09-19 CA CA002232724A patent/CA2232724A1/en not_active Abandoned
- 1996-09-19 AU AU72412/96A patent/AU7241296A/en not_active Abandoned
- 1996-09-19 DE DE69613984T patent/DE69613984T2/de not_active Expired - Fee Related
- 1996-09-19 JP JP9512911A patent/JPH11512601A/ja not_active Withdrawn
- 1996-09-19 AT AT96933833T patent/ATE203271T1/de not_active IP Right Cessation
- 1996-09-19 EP EP96933833A patent/EP0846170B1/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP0846170B1 (de) | 2001-07-18 |
JPH11512601A (ja) | 1999-11-02 |
ATE203271T1 (de) | 2001-08-15 |
AU7241296A (en) | 1997-04-09 |
DE69613984T2 (de) | 2001-11-29 |
US5969117A (en) | 1999-10-19 |
WO1997011171A1 (en) | 1997-03-27 |
CA2232724A1 (en) | 1997-03-27 |
EP0846170A1 (de) | 1998-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI951612A (fi) | Menetelmiä synteettisten oligonukleotidien sekvensoimiseksi, jotka sisältävät nukleotidien välisiä ei-fosfodiesterisidoksia | |
DE69824597D1 (de) | Ikk-beta proteine, nukleinsäuren und verfahren | |
DE69636656D1 (de) | Oligonukleotidliganden mit hoher affinität für pdgf | |
DE69627314D1 (de) | Kettenabbruchgruppen, ihre verwendung zur sequenzierung und synthese von nukleinsäuren und verfahren zu ihrer herstellung | |
LTIP1531A (en) | Method for the determination of dna molecule nucleotides bases sequence | |
ATE328006T1 (de) | Neues protein und verfahren zu dessen herstellung | |
DE3583564D1 (de) | Dna-sequenzen des ebv-genoms, rekombinante dna-molekuele, verfahren zur herstellung von ebv-verwandten antigenen sowie diagnostische zusammensetzungen und pharmazeutische zusammensetzungen, die die genannten antigene enthalten. | |
DE69628864D1 (de) | Invertierte chimäre und hybrid-oligonukleotide | |
DE69634751D1 (de) | MODIFIZIERTE METHIONINASE, DEREN VERWENDUNG, REKOMBINANTE WIRTsZELLEN DIE GROSSE MENGEN VON METHIONINASE PRODUZIEREN UND VERFAHREN ZUR AUFREINIGUNG VON METHIONINASE | |
DE69623005D1 (de) | Verbesserte verfahren zur enzymatischen synthese von oligosacchariden | |
DE60044367D1 (de) | Nichtaggregierende, nichtausschaltende oligomere, nukleotid-analoga enthaltend; verfahren zu deren herstellung und verwendung | |
ATE224736T1 (de) | Kombinationsprodukt, enthaltend eine nukleinsäure und eine substanz, die die extrazellulärematrix desorganisiert, zur verwendung in gentherapie | |
DE69613984D1 (de) | Für die protein-kinase a-spezifische modifizierte oligonukleotide und verfahren zur deren verwendung | |
EP0815114A4 (de) | Nukleinsäuresynthese unter verwendung von mittels licht abspaltbaren schutzgruppen | |
NZ296748A (en) | Peripheral nervous system specific sodium channel proteins, DNA coding therefor, compositions and methods | |
DE69831500T2 (de) | Humane checkpointkinase, hcds1, zusammensetzungen und verfahren | |
EP0641215A4 (de) | Protease-resistente analoge des thrombomodulin. | |
DE69618614D1 (de) | NUKLEINSÄUREMOLEKÜLE MIT DER FÄHIGKEIT ZUR UNTERSCHEIDUNG VON PrPc UND PrPSc-PRIONPROTEIN-ISOFORMEN UND VERFAHREN ZU DEREN HERSTELLUNG | |
ATE296886T1 (de) | Männliche fertilität vermittelnde nukleotidsequenzen und verfahren zu ihrer verwendung | |
DE69637941D1 (de) | Modifizierte hämoglobinähnliche verbindungen und verfahren zu deren reinigung | |
DE69803822D1 (de) | Verbessertes Verfahren zur Hydrierung von Maleinsäure zu 1,4-Butandiol | |
DE3485923D1 (de) | Dna-gen, verfahren zu seiner herstellung und dieses gen enthaltendes plasmid. | |
DE69637516D1 (de) | Verfahren für die Amplifizierung von Nukleinsäure-Sequenzen | |
AU6328598A (en) | Modified protein kinase a-specific oligonucleotides and methods of their use | |
DE59611131D1 (de) | Acarbose-Biosynthesegene aus Actinoplanes sp., Verfahren zu ihrer Isolierung sowie ihrer Verwendung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8339 | Ceased/non-payment of the annual fee |